Management of Gastroesophageal Reflux Disease that does not Respond Well to Proton Pump Inhibitors

Tiberiu Hershcovici and Ronnie Fass

Disclosures

Curr Opin Gastroenterol. 2010;26(4):367-378. 

In This Article

Conclusion

As previously mentioned, the main focus for drug development in refractory GERD patients is TLESR reduction and more potent, early and consistent acid suppression. However, due to the diverse causes of PPI failure, one therapeutic strategy may not be the solution for all patients. It is likely that individually tailored therapy will be the best management approach.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....